DRKS00028021招募中不适用
Characterisation of tumour heterogeneity and identification of adaptive resistance mechanisms of metastatic castration-resistant prostate carcinoma
Klinik für Nuklearmedizin am Universitätsklinikum Augsburg0 个研究点目标入组 45 人开始时间: 2022年3月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one(—)
- 性别
- Male
入选标准
- •Patients between 18 and 99 years of age
- •- Fulfilment of the standard criteria for a 177Lu-PSMA RLT
- •- Low-risk accessibility of a PSMA-positive lesion by percutaneous biopsy
排除标准
- •- Persons who are placed in an institution by court order or by order of the authorities.
- •- Persons who are in a dependent relationship or employment relationship with the sponsor or investigator.
- •- Severe psychiatric illnesses
- •- Patients with congenital bleeding disorders (e.g. von Willebrand disease).
研究者
相似试验
Unknown
不适用
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and metastasesSCLC niet kleincellig longcarcinoom, longkankerlungcancer, tumour heterogeneity, tumor heterogeniteit, CTC, circulating tumour cell, circulerende tumor celNL-OMON29203niversity Medical Centre Groningen30
尚未招募
不适用
Comparing tumour heterogeneity in primary tumour, circulating tumour cells and its metastaseslungcancer1002765510029107NL-OMON45251niversitair Medisch Centrum Groningen50
招募中
2 期
Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.Breast cancer2024-512152-38-00Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela100
尚未招募
Unknown
Fluorodeoxyglucose (FDG) and human epidermal growth factor receptor 2 (HER2) positron emission tomography (PET) scan in breast cancerCancer - BreastBreast cancerACTRN12624000918527Fiona Stanley Hospital10
已完成
不适用
An integrated multi-omics study of tumor heterogeneity in patients with treatment-resistant malignant cancermalignant cancerJPRN-UMIN000040181Kansai Electric Power Hospital100
